Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis

Abstract

Background:

Increased levels of antibodies to neurofilament light protein (NF-L) in biological fluids have been found to reflect neuroinflammatory responses and neurodegeneration in multiple sclerosis (MS).

Objective:

To evaluate whether levels of serum antibodies against NF-L correlate with clinical variants and treatment response in MS.

Methods:

The autoantibody reactivity to NF-L protein was tested in serum samples from patients with relapsing–remitting MS (RRMS) (n=22) and secondary progressive MS (SPMS) (n=26). Two other cohorts of RRMS patients under treatment with natalizumab were analysed cross-sectionally (n=16) and longitudinally (n=24). The follow-up samples were taken at 6, 12, 18 and 24 months after treatment, and the NF-L antibody levels were compared against baseline levels.

Results:

NF-L antibodies were higher in MS clinical groups than healthy controls and in RRMS compared to SPMS patients (p<0.001). NF-L antibody levels were lower in natalizumab treated than in untreated patients (p<0.001). In the longitudinal series, NF-L antibody levels decreased over time and a significant difference was found following 24 months of treatment compared with baseline measurements (p=0.001).

Conclusions:

Drug efficacy in MS treatment indicates the potential use of monitoring the content of antibodies against the NF-L chain as a predictive biomarker of treatment response in MS.

Keywords

Neurofilament light chain antibodies neuroinflammation neurodegeneration natalizumab treatment multiple sclerosis

Get full access to this article

View all access options for this article.

References

Fialova

Bartos

Soukupova

. Synergy of serum and cerebrospinal fluid antibodies against axonal cytoskeletal proteins in patients with different neurological diseases. Folia Biol (Praha) 2009; 55: 23–6.

Tumani

Teunissen

Sussmuth

. Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases. Expert Rev Mol Diagn 2008; 8: 479–94.

Gresle

Butzkueven

Shaw

. Neurofilament proteins as body fluid biomarkers of neurodegeneration in multiple sclerosis. Mult Scler Int 2011; 2011: 315406.

Hoffman

Griffin

Price

. Control of axonal caliber by neurofilament transport. J Cell Biol 1984; 99: 705–14.

Petzold

Gveric

Groves

. Phosphorylation and compactness of neurofilaments in multiple sclerosis: indicators of axonal pathology. Exp Neurol 2008; 213: 326–35.

Stefanis

. alpha-Synuclein in Parkinson’s disease. Cold Spring Harb Perspect Med 2012; 2: a009399.

Ackerley

Grierson

Banner

. p38alpha stress-activated protein kinase phosphorylates neurofilaments and is associated with neurofilament pathology in amyotrophic lateral sclerosis. Mol Cell Neurosci 2004; 26: 354–64.

Bartos

Fialova

Soukupova

. Antibodies against light neurofilaments in multiple sclerosis patients. Acta Neurol Scand 2007; 116: 100–7.

Kuhle

Leppert

Petzold

. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology 2011; 76: 1206–13.

10.

Dujmovic

. Cerebrospinal fluid and blood biomarkers of neuroaxonal damage in multiple sclerosis. Mult Scler Int 2011; 2011: 767083.

11.

Eikelenboom

Petzold

Lazeron

. Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy. Neurology 2003; 60: 219–23.

12.

Couratier

Preud’homme

. Serum autoantibodies to neurofilament proteins in sporadic amyotrophic lateral sclerosis. J Neurol Sci 1998; 154: 137–45.

13.

Ehling

Lutterotti

Wanschitz

. Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosis. Mult Scler 2004; 10: 601–6.

14.

Fialova

Bartos

Svarcova

. Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis. J Neuroimmunol 2013.

15.

Silber

Semra

Gregson

. Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit. Neurology 2002; 58: 1372–81.

16.

Puentes

Topping

Kuhle

. Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2013.

17.

Bornstein

Aronovich

Korczyn

. Antibodies to brain antigens following stroke. Neurology 2001; 56: 529–30.

18.

Hutchinson

Natalizumab: A new treatment for relapsing remitting multiple sclerosis. Ther Clin Risk Manag 2007; 3: 259–68.

19.

Polman

O’Connor

Havrdova

. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899–910.

20.

Polman

Reingold

Edan

. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 2005; 58: 840–6.

21.

Swanton

Rovira

Tintore

. MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: A multicentre retrospective study. Lancet Neurol 2007; 6: 677–86.

22.

Huizinga

van der Star

Kipp

. Phagocytosis of neuronal debris by microglia is associated with neuronal damage in multiple sclerosis. Glia 2012; 60: 422–31.

23.

Amor

Puentes

Baker

. Inflammation in neurodegenerative diseases. Immunology 2010; 129: 154–69.

24.

Kalmar

Malaspina

. A method to solubilise protein aggregates for immunoassay quantification which overcomes the neurofilament “hook” effect. J Neurosci Methods 2011; 195: 143–50.

25.

Miller

. Biomarkers and surrogate outcomes in neurodegenerative disease: Lessons from multiple sclerosis. NeuroRx 2004; 1: 284–94.

26.

Bitsch

Schuchardt

Bunkowski

. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 2000; 123 (Pt 6): 1174–83.

27.

Schirmer

Merkler

Konig

. Neuroaxonal regeneration is more pronounced in early multiple sclerosis than in traumatic brain injury lesions. Brain Pathol 2013; 23: 2–12.

28.

Rice

Hartung

Calabresi

. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 2005; 64: 1336–42.

29.

Gensicke

Leppert

Yaldizli

. Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis. CNS Drugs 2012; 26: 11–37.

30.

Yaldizli

Putzki

. Natalizumab in the treatment of multiple sclerosis. Ther Adv Neurol Disord 2009; 2: 115–28.

31.

Gunnarsson

Malmestrom

Axelsson

. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 2011; 69: 83–9.

32.

Kuhle

Malmestrom

Axelsson

. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis. Acta Neurol Scand 2013; 128: e33–6.

33.

Fialova

Bartos

Svarcova

. Increased intrathecal high-avidity anti-tau antibodies in patients with multiple sclerosis. PLoS One 2011; 6: e27476.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.17 MB